A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study

BACKGROUND: Prognosis remains poor after progression on first-line chemotherapy for colorectal adenocarcinoma, and inactivation of the EGFR pathway with monoclonal antibodies is an effective treatment strategy in selected patients with metastatic disease. Lapatinib is an oral EGFR and HER-2 dual tyr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Frank, Daniel, Jumonville, Alcee, LoConte, Noelle K, Schelman, William R, Mulkerin, Daniel, Lubner, Sam, Richter, Katie, Winterle, Natalie, Wims, Mary Beth, Dietrich, Leah, Winkler, J. Mitchell, Volk, Michael, Kim, KyungMann, Holen, Kyle D.
Formato: Artigo
Idioma:Inglês
Publicado em: Pioneer Bioscience Publishing Company 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397648/
https://ncbi.nlm.nih.gov/pubmed/22811876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2011.049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados